Clinical Trials

Infectious Disease & Vaccines

He feared the influenza pandemic would steal time with his granddaughter.

They just perfected their chocolate chip cookie recipe.

That is what drives us. Experience, Rho.

Infectious Disease

Now more than ever, as global pandemics such as COVID-19 and other infectious diseases threaten people’s lives across the globe, demanding an adaptable CRO partner with Medical Counter Measures expertise and a track record of delivering relief when and where it’s needed isn’t just important – it’s critical.

Passionately fighting to protect the health of our nation since 1997, Rho has conducted more than 175 infectious disease studies at 300+ sites and over 100,000 patients. With virtual trial experience and vast infectious disease expertise extending from program strategy through clinical trials and marketing applications, as well as long-standing relationships with NIH, NIAID, and BARDA, Rho possesses a distinct advantage when navigating the challenges common to this therapeutic area, including decentralization and those related to safety and labs, at-risk populations, compliance, genotype/phenotype vendors, and retention.

Seeking fast development and approval for your COVID-19 related product?

Learn more

Infectious Disease & Vaccines Expertise


clinical trials


clinical sites



Why Choose Rho?

2 recent NDA submissions to CDER Division of Anti-Infective Products

1 of 5 CROs chosen for the BARDA Medical Counter Measures Clinical Studies Network (CSN)

Awarded Statistical, Data and Clinical Coordinating Center by the National Institutes of Allergy and Infectious Disease (NIAID)

23+ years of industry-leading federal research experience

Through strong and ongoing relationships with the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Department of Health and Human Services (DHHS), and 1 of only 5 infectious disease and vaccine contract research organizations chosen to be in the BARDA Medical Counter Measures (MCM) Clinical Studies Network, Rho continues to be called upon to assist the U.S. Government in the development of drugs, vaccines and diagnostics that help ensure public safety against the threat of pandemics, bioterrorism and emerging diseases.

Our interactions with BARDA over the last 6 years have given us a deep familiarity with the priorities, personnel, processes, and vendors that drive BARDA’s medical countermeasures research. The knowledge gained through our BARDA interactions means that we can offer quality support and guidance on BARDA’s preferences for study conduct. For example:

  • We have extensive experience with vendors already approved by BARDA
  • We have quality systems and project plans in place that have been approved by BARDA
  • We understand that BARDA values cross-functional team integration (e.g. partnering with their CROs to attending monitoring visits and audits)

BARDA MCM studies awarded to Rho, include:

If you’re looking to acquire BARDA funding for your clinical trial or program, our experts can provide strategic guidance to help set you up for success.

Learn more about our BARDA funding consulting services

As the Clinical Trial Manager for a Sponsor Organization, I have had the distinct privilege of working with Rho. I continue to be impressed with the support we receive from Rho, especially in light of the COVID-19 pandemic. The pandemic presented us with challenges leading to modifications to our ongoing protocol-specified procedures. However, with the implementation of pragmatic design aspects focused on data integrity and the safety monitoring of our patients, we were able to continue our trial without interruption.

Current COVID-19 Clinical Trial Support

Currently, our experts are conducting clinical trials for COVID-related products, including a 6,000 patient study of Coronavirus infection rates in children, which is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study is breaking new ground in the conduct of virtual trials by allowing patients to complete the study almost entirely from home, including the self-collection of nasal swab, blood, and stool samples.

Additionally, since the pandemic began, Rho has worked with many sponsors to provide trial and site selection strategies in support of their planned COVID-19 treatment and vaccine studies. This includes extensive site feasibility to determine COVID-19 infection rates at the state and county level, PPE availability and needs at the site level, and determining the geographic location of the highest bolus of subjects, based on projected outbreak forecasts of 4-8 weeks out.

Conducting research during the 2009 H1N1 pandemic

During the 2009 H1N1 pandemic, the NIH turned to Rho to rapidly develop and coordinate a national, multisite research project to evaluate the immunogenicity and dosing of the H1N1 vaccine in those with asthma. Rho supported the trial from protocol development through publication of study results.

In less than 18 months, the study team went from the initial study idea to publication of the primary study results in the Journal of Allergy and Clinical Immunology. Read the case study.

Join us on our mission to passionately protect the health of our nation against any and all threats posed by infectious diseases. We proudly invite you to experience Rho.


Indications Expertise

Considerations for Starting a Vaccine Study

This article discusses the risks, challenges, and solutions needed to operationalize a vaccine clinical trial.

Success Stories

Research Success During the 2009 H1N1 Pandemic

Read more

Fast Enrolling Influenza Vaccine Study

Read more

Approval for a Product that Fights Drug-Resistant Tuberculosis Using FDA’s LPAD Program

Read more

Featured Content


Considerations for Starting Up Your COVID-19 Study Quickly

Read more

Programs to Support Drug Development in Infectious Disease: GAIN, QIDP, and LPAD

Read more
Blog Post

Considerations for Implementing Decentralized Clinical Trials

Read more